Replies to post #32523 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Thanks for compiling those initial 3 questions wimusky. I hope other longs join ya and we get a nice list compiled ahead of next weeks CC>>>

1. Please elaborate on the latest Chinese deal that is in process?
2. What is Dr Odidi's relationship to the Smart Pharma entity? Is Dr. Odidi one of the owners of Smart Pharma? Did Dr. Odidi found Smart Pharma?
3. What is expected 2018 revenue for Seroquel XR?

4. At what exact point on the calendar was IPCI's last communication with the FDA pertaining to the status of both the Pristiq and Lamictal ANDA's?

5. How much will the approx. 6 month oral and nasal CAT 2 & 3 HAP studies cost?

6. How much will the human trails cost on PODRAS and how long will the initial human trials last?

7. If there's no ANDA approvals on Pristiq and Lamictal soon, when does mgmt. envision that IPCI will require another offering?

8. Is mgmt. going to be attending any investor presentation conferences as they have in the past? The last such attendance at any investor conference by anyone at IPCI mgmt. was over 1 year ago.

9. Can mgmt. please elaborate on the following statement from IPCI's most recent shareholder update PR? As the Company builds its product portfolio, we are also seeking to add additional product development candidates to our pipeline. We have received considerable interest and are investigating several opportunities to develop products in collaboration with international partners. Are these potential new product candidates ANDA's or NDA's or a combination of both? And what international areas are these potential collaborative partners based in? Are we talking about China or other international markets?

10. What happened to the 20 other opioid based NDA product candidates that were said to be in IPCI's product development pipeline? Does mgmt. still have plans to file additional opioid based NDA's and if so within what timeframe?

11. The most recent shareholder update PR specifically states that IPCI is planning on launching phase III studies on their Regabatin NDA candidate in the back half of this year. Does that mean that IPCI will need to secure a partner before launching those studies in order for mgmt. to deliver on that now telegraphed timeline to execution of phase III studies?

12. If IPCI does do another offering soon can mgmt. assure shareholders that there will not be a reverse split?

That's all I have for now...hopefully other longs will add to and/or edit the initial dozen questions compiled.